Skip Navigation



Rheumatology Advance Access published online on November 6, 2008

Rheumatology, doi:10.1093/rheumatology/ken402
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
48/1/89    most recent
ken402v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jayachandran, N. V.
Right arrow Articles by Narsimulu, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jayachandran, N. V.
Right arrow Articles by Narsimulu, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Cyclophosphamide-associated complications: we need to be aware of SIADH and central pontine myelinolysis

N. V. Jayachandran1, P. K. S. Chandrasekhara1, J. Thomas1, S. Agrawal1 and G. Narsimulu1

1Department of Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad, Andhra Pradesh, India

Correspondence to: G. Narsimulu, Department of Rheumatology, Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad 500 082, Andhra Pradesh, India. E-mail: narsimulunims{at}hotmail.com

SIR, We report a case highlighting a rare complication that rheumatologists might come across while using cyclophosphamide.

A 49-yr-old lady with dcSSc for 2 yrs, presented with cough and dyspnoea on exertion of 4 months duration. Clinical examination, HRCT-thorax and pulmonary function test revealed interstitial lung disease with severe restrictive abnormality. She was started on monthly pulses of intravenous cyclophosphamide (500 mg) and oral prednisolone (20 mg/day).

A day after the second pulse, she presented with extreme fatigue and restlessness. There was no history of fever, chest pain or headache. Investigations revealed hyponatraemia (serum Na 106 meq/l) and she was started on 0.9% normal saline. Over the next 12 h her consciousness deteriorated. She had two episodes of generalized tonic–clonic seizures and became comatose. Serum sodium did not improve.

At this time, the urine osmolality was found to be high (620 mOsmol/kg) with low-plasma osmolality (248 mOsmol/kg) and normovolaemia. These features were consistent with syndrome of inappropriate antidiuretic hormone secretion (SIADH) possibly related to cyclophosphamide infusion since no other underlying cause could be identified. Fluids were restricted. As she had altered consciousness and seizures, we tried to correct hyponatraemia with hypertonic saline. Sodium deficit was calculated and 3% saline initiated at 15 ml/h. The consciousness improved 24 h after initiating hypertonic saline, but again deteriorated over the next 24 h. CSF examination was normal. Blood and urine cultures were negative. MRI-brain at this stage was normal. She remained in coma despite the serum sodium becoming normal. There were no further seizures. A repeat MRI done after a week showed typical features of central pontine myelinolysis (CPM) (Fig. 1). The patient continues to be comatose till the time of writing this report which is about 3 months after the event.


Figure 1
View larger version (127K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
FIG. 1. T2-weighted image showing triangular area of hyperintensity in the basis pontis suggestive of central pontine myelinolysis.

 
SIADH is the most frequent cause of normovolaemic hyponatraemia [1]. Cyclophosphamide can also produce SIADH [2]. This is, however, usually known with higher doses used in oncology practice [3]. In the present case, this complication was seen at a relatively lower dose (500 mg). There are only a few reports of low-dose intravenous cyclophosphamide causing SIADH [4, 5].

CPM is a well-known complication encountered while correcting hyponatraemia [6]. Both prolonged hyponatraemia as well as rapid correction of it can cause CPM [7]. In this case, both might have contributed to this complication. But what this case highlights is that SIADH, although uncommon with low-dose cyclophosphamide, is nevertheless an important complication one should keep in mind while using this drug irrespective of the dosage.

Formula

Disclosure statement: The authors have declared no conflicts of interest.


    References
 Top
 References
 

  1. Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatremia in medical cancer patients: epidemiology, etiology and differential diagnosis. Support Care Cancer (2000) 8:192–7.[CrossRef][Web of Science][Medline]
  2. Janicic N, Verbalis JG. Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am (2003) 32:459–81.[CrossRef][Web of Science][Medline]
  3. Bressler RB, Huston DP. Water intoxication following moderate-dose intravenous cyclophosphamide. Arch Intern Med (1985) 145:548–9.[Abstract/Free Full Text]
  4. Salido M, Macarron P, Hernández-García C, D’Cruz DP, Khamashta MA, Hughes GR. Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus. Lupus (2003) 12:636–9.[Abstract/Free Full Text]
  5. McCarron MO, Wright GD, Roberts SD. Water intoxication after low dose cyclophosphamide. Br Med J (1995) 311:292.[Free Full Text]
  6. Laureno R, Karp BI. Myelinolysis after correction of hyponatremia. Ann Intern Med (1997) 126:57–62.[Abstract/Free Full Text]
  7. Singer GG, Brenner BM. Fluid and electrolyte disturbances. In: Harrison's principles of internal medicine—Braunwald E, Fauci AS, Kasper DL, et al, eds. (2005) 16th edition. New York: McGraw Hill. 258–61.
Accepted 16 September 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
48/1/89    most recent
ken402v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jayachandran, N. V.
Right arrow Articles by Narsimulu, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jayachandran, N. V.
Right arrow Articles by Narsimulu, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?